NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
Betsy Goodfellow | May 18, 2023 | News story | Medical Communications | Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care Excellence (NICE) has recommended Kapruvia for the treatment of moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.
This recommendation follows authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in April 2022.
Fabio Dorigotti, head global medical affairs of CLS Vifor, commented: “The recommendation of Kapruvia by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK. We look forward to continue working with the NHS to ensure access to this important medicine for patients as quickly as possible.”
Christopher Posner, president and CEO of Cara Therapeutics, added: “We are pleased that Kapruvia will be available to CKD patients in England, Wales and Northern Ireland who are undergoing haemodialysis and suffering from moderate-to-severe CKD-associated pruritus. Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed.”
Dr Kieran McCafferty, consultant nephrologist at Barts Health NHS Trust, stated: “Chronic kidney disease-related itch is common for people on haemodialysis and represents a significant unmet need; leading to poor sleep and reduced quality of life for patients. We now have an option to help reduce the burden of CKD-related itch.”
Betsy Goodfellow
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
